Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia
Open accessAbstract
BACKGROUND: There is currently insufficient evidence to either support or refute an association between estrogen-based hormone treatment (EBHT) and thrombosis risk in essential thrombocythemia (ET). METHODS: A retrospective review of thrombotic events, which occurred both at diagnosis of ET and during subsequent follow-up, was performed in a consecutive cohort of women with WHO-defined ET seen at the Mayo Clinic. Details of EBHT were concomitantly obtained. RESULTS: A total of 305 women were seen during the study period and followed for a median of 133 months. EBHT at diagnosis was documented in 59 women and such therapy was instituted at a variable time after diagnosis in 34 additional patients. At diagnosis, major thrombosis occurred in 73 patients (24%), including 11 of 59 (19%) on EBHT and 62 of 246 (25%) not on EBHT (P=.28). Thrombosis after diagnosis occurred in 94 patients (31%), including 64 of 212 (30%) not on EBHT, 5 of 17 (29%) in whom EBHT was discontinued at diagnosis, 13 of 42 (31%) in whom EBHT was continued despite the diagnosis of ET, and 12 of 34 (35%) in whom EBHT was started after diagnosis (P=.95). The overall results were the same when arterial and venous events were analyzed separately. However, EBHT in the form of oral contraceptives (OCP) was associated with an increased risk of venous thrombosis (P=.03). CONCLUSIONS: EBHT is safe in ET outside the setting of OCP use, which might be associated with an increased risk of deep vein thrombosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the same study, CHC use was associated with a threefold increase of VTE and a fivefold increased risk of splanchnic thrombosis.
“However, CHC use was associated with a threefold increase of VTE (HR), and a fivefold increased risk of splanchnic thrombosis (HR) [115]”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [115]
In a study of 305 female patients with essential thrombocythemia, the use of MHT was not associated with an increase in venous or arterial thrombotic events.
“In one study of 305 female patients with essential thrombocythemia by Gangat et al, the use of MHT was not associated with an increase in venous or arterial thrombotic events.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 32 · Cited by 37
Research works printed but not linked: 5
- Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press, 2001:17-44.
- Tefferi A, Gilliland DG. Classification of myeloproliferative disorders: from Dameshek towards a semi-molecular sys- tem. Best Pract Res Clin Haematol. 2005 (in press).
- Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol. 1999;61:10- 15.
- Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myelopro- liferative disorders. Cancer. 1991;67:2658-2663.
- Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea com- pared with anagrelide in high-risk essential thrombocythe- mia. N Engl J Med. 2005;353:33-45.
- Authors
- Gangat, N., Wolanskyj, A. P., Schwager, S. M., Mesa, R. A., & Tefferi, A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Tefferi, Ayalew
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-05-18
- Volume
- 106
- Issue
- 11
- Pages
- 2406-2411
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2054999400
- Cited by
- 37
- References
- 32
- Citations by year
- 2025: 6 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 2
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- essential thrombocythemia, thrombosis risk, oral contraceptives, venous thrombosis, deep vein thrombosis, arterial thrombosis, women
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Retrospective Studies, Risk Factors, Thrombocytosis, Thrombosis, Estrogen Replacement Therapy, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
